The market for the treatment of oral mucositis is becoming more and more significant in the field of supportive care in oncology owing to the rising prevalence of cancers around the world and increasing cases of patients receiving chemoradiation therapy or hematopoietic stem cell transplantation. Oral mucositis is one of the major side effects associated with the treatment of cancer that leads to inflammation, ulcers, pain in eating and swallowing, and poor quality of life.
Oral Mucositis Treatment Market valued at USD 1.79 billion in 2024 and is anticipated to reach USD 3.12 billion by 2032, witnessing a CAGR of 7.26% throughout the forecast period of 2025 to 2032. Key drivers of market growth include the increasing prevalence of cancer, rising usage of chemotherapy and radiotherapy, growing awareness about associated complications, and continuous developments in treatment technologies. Adoption of low-level laser therapy, bioadhesive gels, anti-inflammatory agents, protective mouthwashes, and many other supportive care options are also driving market growth.
To Get More Information on Oral Mucositis Treatment Market – Request Free Sample Report
Top 4 Oral Mucositis Treatment Companies
1. Napo Pharmaceuticals
Napo Pharmaceuticals is enhancing its position in the market of oral mucositis treatment solutions by venturing into the oncology supportive care segment. Its emphasis on specialized therapeutic products makes it well-positioned to capitalize on the rising trend of increased demand for therapies that would improve the quality of life of patients and ease the management of complications of cancer treatment. In April 2024, Napo Pharmaceuticals has broadened its oncology supportive care portfolio by in-licensing Gelclair to treat oral mucositis. Napo Pharmaceuticals has confirmed its plans to bring Gelclair to market for patients undergoing cancer treatment.
2. Soligenix, Inc.
Soligenix is a key player in the discovery of new therapies that will help treat inflammatory and mucosal conditions. Research being conducted by Soligenix is especially pertinent to the changing oral mucositis therapy market, which is experiencing growing need for therapeutic options that will minimize both the severity and duration of the lesions. On January 25, 2024, Soligenix reported that SGX945, which is also known as dusquetide, has been granted the status of Fast Track Designation by the U.S. Food and Drug Administration as a treatment of oral lesions in Behçet's Disease patients.
3. Helsinn Healthcare SA
Helsinn Healthcare SA has a presence in supportive care and solutions for cancer patients, which makes it a significant player in the overall market for treatment of oral mucositis. The increasing focus on enhancing the quality of life of patients undergoing cancer treatment is creating opportunities for such companies. With an increased emphasis being placed on addressing the side effects of cancer treatment alongside providing oncological treatments, Helsinn Healthcare is likely to benefit from growing market demands for such supportive treatments. The development of more specialized drugs, protective treatments, and easier-to-administer formulations will be among the market activities that will continue to dominate.
4. Galera Therapeutics, Inc.
Galera Therapeutics is involved in the development of therapies addressing conditions associated with cancer treatment, positioning the company within the evolving supportive oncology care ecosystem. The growing clinical and commercial focus on reducing complications caused by chemotherapy and radiotherapy is increasing interest in innovative approaches to mucosal protection and tissue recovery. The increasing use of aggressive cancer treatment protocols is expected to sustain demand for therapies that can help manage oral mucositis and related complications. Companies engaged in the development of radiation-associated supportive therapies are therefore expected to play an increasingly important role as healthcare providers seek to improve treatment tolerance and patient outcomes.
What is Driving the Growth of the Oral Mucositis Treatment Market?
Rising cancer cases across the globe are one of the important drivers for market growth. Patients under chemotherapy and radiotherapy therapy often suffer from cell damage, especially on the lining of the oral cavity which is extremely sensitive. This may cause inflammation, ulcers, pain, and problems with adequate nutrition and mouth cleaning. The occurrence of oral mucositis is highly relevant for those patients who get intensive therapy for head and neck cancers and hematological malignancies. There are plenty of reports of occurrence of oral mucositis among patients who underwent hematopoietic stem cell transplantation. With the increasing number of patients who need intensive cancer treatment, the demand for supportive products will only grow.
New developments in the treatment methodologies are helping to drive this market even further. The conventional methodologies used for pain treatment have proven useful, but healthcare professionals are now considering treatment modalities which not only focus on addressing the inflammation but also fast recovery from it. Low level laser therapy and photobiomodulation have received attention due to its ability to lower the severity of the oral mucositis as well as the pain. Specialized bioadhesive gels and mouthwashes as well as cytokine therapies among others are becoming part of treatment modalities.
The Road Ahead
The future trend for the Oral Mucositis Treatment Market would revolve around the development of advanced supportive care strategies in oncological treatments. With the increasing complexity and number of cancer treatments, it would become imperative to manage side effects, including oral mucositis. In addition, the development of new technologies involving low-level laser therapy, bioadhesive formulations, protective mouth rinses, and anti-inflammatory therapy, among others, would increase the number of treatment options for oral mucositis. There would also be an increased focus on prevention and intervention at an early stage of mucositis.
The Oral Mucositis Treatment Market is poised for strong growth prospects till 2032 due to rising cases of cancer, greater health care investments, and the ongoing development of supportive treatment methods for patients. Companies that specialize in clinically proven and user-friendly treatment options can play an instrumental role in influencing the future of the market.
